Vitality Biopharma Inc (OTCMKTS:VBIO) is in two highly volatile industries- Cannabis and Biopharma. Cannabis related biopharma is a buzzword that has become an important industry term the investing world realizes will deliver revenues that have nothing to do with retail pot sales.
Vitality Biopharma Inc (OTCMKTS:VBIO) is in the business of biopharma, and they released one of the first clinical reports detailing the ability of cannabinoid therapy to induce remission in a pediatric inflammatory bowel disease patients as solutions for Crohn’s disease and colitis where patients seek healthier solutions. VBIO published a study on this subject and it has given some lift to the stock recently.
The report is a case study titled, “Induction of Remission in Drug-Resistant Pediatric Inflammatory Bowel Disease with Cannabinoid Therapy,” and describes a 13-year-old boy with drug-resistant Crohn’s disease and colitis who achieved clinical remission after oral administration of cannabinoids. Independently from the Company, the patient received treatment with medical cannabis pursuant to the State of California’s Compassionate Use Act.
The case study describes how the patient’s disease could not be controlled by currently-approved pharmaceuticals, and how cannabinoid treatment led to near-immediate clinical improvement that was indicative of disease remission. The report by Vitality Biopharma and its collaborators is a preprint scientific manuscript that has not yet been subjected to peer review, and additional case reports may be included prior to formal publication.
Clinical trials in IBD patients have previously shown that use of cannabis is associated with substantial symptomatic relief, and placebo-controlled trials have confirmed significant declines in disease activity score after treatment. However, these trials largely relied on subjective outcome measures. The case study detailed by Vitality Biopharma and its collaborators is one of the first where multiple objective measures of disease outcome were reported. This included analysis of fecal calprotectin levels, which increase when lesions or tears in the intestinal tract are present, and decrease when healing of the gut mucosal lining occurs. The case study results provide objective evidence that cannabinoids may not only resolve symptoms of IBD, but also modify disease through reduction of gut inflammation.
Subscribe below and we’ll keep you on top of what’s happening before $VBIO stock makes its next move.
$VBIO 10-Day Chart Below:Vitality Biopharma, Inc (OTCMKTS:VBIO) is a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, and in March of 2017 they announced the filing of an international patent application that describes compounds discovered to be effective in a drug screening model of neural repair.
The underlying patent rights, which were assigned to Vitality Biopharma in March 2016, are based on work performed by the Myelin Repair Foundation (MRF), a non-profit disease research organization that was dedicated to developing regenerative therapies for multiple sclerosis. The results were also published within the scientific journal BMC Neuroscience, in an article titled, “Development of a central nervous system axonal myelination assay for high throughput screening.” Researchers discovered several investigational and FDA-approved drugs that are useful in effecting remyelination, a form of nervous system regeneration.
The discoveries included a compound that is known to have a positive track record of safety in clinical trials and to provide pain relief through modulation of the vanilloid TRPV1 receptor. Cannabidiol (CBD), the well-known cannabinoid that is not intoxicating and that pharmaceutical companies are developing primarily for epilepsy, is also known to relieve pain through modulation of the TRPV1 receptor. As a result, Vitality Biopharma has made broad patent claims covering use of CBD and other TRPV1 agonists for myelin repair and for treatment of demyelinating disorders.
“Part of our mission is to develop treatments that provide far more than symptomatic relief,” said Robert Brooke, Chief Executive Officer of Vitality Biopharma. “We’re excited to further explore the ability of CBD and similar compounds to deliver regenerative benefits for patients with MS and other demyelinating conditions.”
Vitality Biopharma, Inc. (OTCMKTS:VBIO) shares had a run-up in December 2016 to $4.00 keeping the level of excitement high into year end. 2017 has been somewhat sideways trading in the low $2.00 range, but recently shares have headed higher, we will be keeping an eye on how business progresses – as this magic plant – introduces new companies who have cures and solutions for many who suffer these debilitating diseases solvable with cannabis in the new age of medicine treating inflammation. For continuing coverage on shares of $VBIO stock, as well as our other hot stock picks, sign up for our free newsletter today and get our next hot stock pick!